Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: Results from NEWEST, a randomized Phase II study

Breast Cancer Research and Treatment

Volumn 133, Issue 1, 2012, Pages 237-246

  Kuter, Irene ^a   Gee, Julia M W ^b   Hegg, Roberto ^c   Singer, Christian F ^d   Badwe, Rajendra A ^e   Lowe, Elizabeth S ^f   Emeribe, Ugochi A ^f   Anderson, Elizabeth ^j   Sapunar, Francisco ^j   Finlay, Pauline ^b   Nicholson, Robert I ^b   Bines, José ^g   Harbeck, Nadia ^h,i  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e TATA MEMORIAL HOSPITAL   (India)

^f ASTRAZENECA   (United Kingdom)

^g Instituto de Cancer   (Brazil)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j NONE

more..

Author keywords

Biomarkers; Estrogen receptor positive breast cancer; Faslodex ; Fulvestrant 500 mg; Neoadjuvant

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BACKACHE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE MARKER; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERTENSION; INJECTION SITE PAIN; LIMB PAIN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PAIN; PARTIAL MASTECTOMY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; VOMITING; WOUND INFECTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84860322213     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1947-7     Document Type: Article

References (18)

1. KD Bauer J de la Torre-Bueno IJ Diel D Hawes WJ Decker C Priddy B Bossy S Ludmann K Yamamoto AS Masih FP Espinoza DS Harrington 2000 Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging Clin Cancer Res 6 3552 3559 10999743 1:STN:280:DC%2BD3cvkslWksw%3D%3D
2. KL Cheung JF Robertson 2001 Preoperative hormone therapy trials for breast cancer Breast 10 1 5 14965549 10.1054/brst.2000.0201 1:STN:280: DC%2BD2c%2Fns1eltQ%3D%3D
3. S Chia W Gradishar L Mauriac J Bines F Amant M Federico L Fein G Romieu A Buzdar JFR Robertson A Brufsky K Possinger P Rennie F Sapunar E Lowe M Piccart 2008 Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 1664 1670 18316794 10.1200/JCO.2007.13.5822 1:CAS:528:DC%2BD1cXltlWhsrg%3D
4. DJ DeFriend A Howell RI Nicholson E Anderson M Dowsett RE Mansel RW Blamey NJ Bundred JF Robertson C Saunders H Baum P Walton FA Sutcliffe AE Wakeling 1994 Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer Cancer Res 54 408 414 8275477 1:STN:280: DyaK2c7gtFKisQ%3D%3D (Pubitemid 24053178)
5. A Di Leo G Jerusalem L Petruzelka I Bondarenko R Khasanov D Verhoeven J Pedrini I Smirnova M Lichinitser K Pendergrass S Garnett JPO Lindemann F Sapunar M Martin on behalf of the CONFIRM investigators 2010 Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer J Clin Oncol 28 4594 4600 20855825 10.1200/JCO.2010.28.8415 1:CAS:528: DC%2BC3cXhsFaitLzO
6. W Eiermann S Paepke J Appfelstaedt A Llombart-Cussac J Eremin J Vinholes L Mauriac M Ellis M Lassus HA Chaudri-Ross M Dugan M Borgs Letrozole Neo-Adjuvant Breast Cancer Study Group 2001 Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann Oncol 12 1527 1532 11822750 10.1023/A:1013128213451 1:STN:280:DC%2BD38%2FptlGisw%3D%3D (Pubitemid 34065880)
7. ME Hammond DF Hayes AC Wolff PB Mangu S Temin 2010 American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Oncol Pract 6 195 197 21037871 10.1200/JOP.777003
8. Jasani B, Douglas-Jones A, Rhodes A, Wozniak S, Barrett-Lee PJ, Gee J, Nicholson R (2006) Measurement of estrogen receptor status. In: Brooks SA, Harris A (eds) Methods in molecular medicine: breast cancer research protocols, 1st edn. Humana Press, New York
9. W Messersmith D Oppenheimer J Peralba V Sebastiani M Amador A Jimeno E Embuscado M Hidalgo C Iacobuzio-Donahue 2005 Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis Cancer Biol Ther 4 1381 1386 16319527 10.4161/cbt.4.12.2287 1:CAS:528:DC%2BD28XkvVOgsr4%3D (Pubitemid 43131184)
10. JF Robertson B Erikstein KC Osborne J Pippen SE Come LM Parker S Gertler MP Harrison DA Clarke 2004 Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer Clin Pharmacokinet 43 529 538 15170367 10.2165/00003088-200443080-00003 1:CAS:528:DC%2BD2cXlvFOlt7Y%3D (Pubitemid 38858305)
11. JF Robertson A Llombart-Cussac J Rolski D Feltl J Dewar E Macpherson J Lindemann MJ Ellis 2009 Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study J Clin Oncol 27 4530 4535 19704066 10.1200/JCO.2008.21.1136 1:CAS:528:DC%2BD1MXhtlCns77J
12. JF Robertson RI Nicholson NJ Bundred E Anderson Z Rayter M Dowsett JN Fox JM Gee A Webster AE Wakeling C Morris M Dixon 2001 Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl] estra-1,3,5 (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer Cancer Res 61 6739 6746 11559545 1:CAS:528:DC%2BD3MXntFaisLw%3D (Pubitemid 32896496)
13. Robertson JFR, Lindemann J, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Emerson L, Dean A, Ellis MJ (2010) A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the 'FIRST' study. Cancer Res 70: abstract S1-S3
14. JFR Robertson A Llombart J Rolski D Feltl J Dewar E Macpherson J Lindemann MJ Ellis 2009 Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study J Clin Oncol 27 4530 4535 19704066 10.1200/JCO.2008.21.1136 1:CAS:528:DC%2BD1MXhtlCns77J
15. JFR Robertson CK Osborne A Howell SE Jones L Mauriac M Ellis UR Kleeberg SE Come I Vergote S Gertler A Buzdar A Webster C Morris 2003 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials Cancer 98 229 238 12872340 10.1002/cncr.11468 1:CAS:528:DC%2BD3sXlvFCiu7g%3D (Pubitemid 36828445)
16. IE Smith M Dowsett SR Ebbs JM Dixon A Skene JU Blohmer SE Ashley S Francis I Boeddinghaus G Walsh IMPACT Trialists' Group 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108 5116 15998903 10.1200/JCO.2005.04.005 1:CAS:528:DC%2BD2MXpsFWmtLY%3D (Pubitemid 46224019)
17. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
18. S Wang MH Saboorian EP Frenkel BB Haley MT Siddiqui S Gokaslan FH Wians Jr L Hynan R Ashfaq 2001 Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard Am J Clin Pathol 116 495 503 11601134 10.1309/TMUW-G4WB-LXJ2-FUDN 1:STN:280:DC%2BD3MrlsVyjtg%3D%3D (Pubitemid 34450283)